15 November 2022 LungLife AI, Inc. ("LungLife" or the "Company") Block Listing Six Monthly Return LungLife AI (AIM: LLAI), a developer of clinical diagnostic solutions for lung cancer, makes the following six-monthly update on its block listing: Name of applicant: LungLife AI, Inc. Name of scheme: 2010 Stock Incentive Plan 2020 Stock […]
LungLife AI, Inc. (the “Company” or “LungLife”) Director share purchases LungLife AI (AIM: LLAI), a developer of clinical diagnostic solutions for lung cancer, announces that it has received notification of the following transactions in the Company’s common shares of US $0.0001 each (“Common Shares”) undertaken by directors. On 2 November 2022, Paul Pagano, Chief Executive […]
LungLife AI licensure/accreditation information posted here.